Pharma News

The day in pharma, read in minutes.

Updated Nov 13, 2026

Latest news

11 stories
NewsNew

Eros Apothecary Recalls Honey Supplement Over Tadalafil

Eros Apothecary recalls honey supplement after FDA lab testing detects undeclared tadalafil, flagging e-commerce supply chain oversight gaps.

Vaibhavi M.Nov 13, 2026Read more
Eros Apothecary Recalls Honey Supplement Over Tadalafil
NewsNew

Artelo Reports 40% Weight Loss with Semaglutide in Mice

Artelo's ART27.13 achieves ~40% weight loss combined with semaglutide in nonclinical model; U.S. patent protection expected through 2041.

Vaibhavi M.Nov 12, 2026Read more
Artelo Reports 40% Weight Loss with Semaglutide in Mice
News

Grace Therapeutics Advances Dual-Source CMO Strategy

Grace Therapeutics pursues dual-source CMO strategy for GTx-104 after FDA CRL flags CMC deficiencies, with NDA resubmission tied to whichever site clears readiness first.

Vaibhavi M.Nov 12, 2026Read more
Grace Therapeutics Advances Dual-Source CMO Strategy
News

Monopar Therapeutics Nears Rolling NDA Completion for ALXN1840

Monopar's rolling NDA for ALXN1840 in Wilson disease nears completion, with Phase 3 baseline data and six-year safety findings now on record.

Vaibhavi M.Nov 12, 2026Read more
Monopar Therapeutics Nears Rolling NDA Completion for ALXN1840
News

Kiora Pharmaceuticals Advances KIO-401 IND Pathway

Kiora Pharmaceuticals submits Type B pre-IND request for KIO-401, a calpain inhibitor backed by Japanese Phase 2/3 data, targeting CRAO.

Vaibhavi M.Nov 12, 2026Read more
Kiora Pharmaceuticals Advances KIO-401 IND Pathway
News

Johnson & Johnson Secures Second Phase 3 Win for CAPLYTA

J&J's CAPLYTA meets primary YMRS endpoint in a second Phase 3 trial, clearing the clinical bar for an sNDA filing in bipolar I mania.

Vaibhavi M.Nov 12, 2026Read more
Johnson & Johnson Secures Second Phase 3 Win for CAPLYTA
News

FDA Finalizes GFI 273 on Antimicrobial Use in Food Animals

FDA's GFI #273 sets duration-of-use recommendations for veterinary antimicrobials, raising the compliance bar for animal drug sponsors.

Vaibhavi M.Nov 12, 2026Read more
FDA Finalizes GFI 273 on Antimicrobial Use in Food Animals
News

ProQR Therapeutics Advances RNA Editing Pipeline

ProQR reports full enrollment in AX-0811 Phase 1 cohorts and targets multiple clinical milestones through H1 2027, with €103M cash runway into mid-2028.

Vaibhavi M.Nov 12, 2026Read more
ProQR Therapeutics Advances RNA Editing Pipeline
News

FibroBiologics Expands Patent Portfolio to 170 Issued Patents

FibroBiologics reaches 170 issued patents covering fibroblast therapeutics and manufacturing methods, raising IP complexity for CDMOs entering the space.

Vaibhavi M.Nov 12, 2026Read more
FibroBiologics Expands Patent Portfolio to 170 Issued Patents
News

Dr. Reddy's Secures Brazil Approval for Generic Semaglutide

ANVISA clears Dr. Reddy's generic semaglutide injection for type 2 diabetes, opening a referenceable regulatory pathway for GLP-1 generics in Brazil.

Vaibhavi M.Nov 7, 2026Read more
Dr. Reddy's Secures Brazil Approval for Generic Semaglutide
News

Janssen Wins Full FDA Approval for Erdafitinib

Janssen's erdafitinib converts to full FDA approval in FGFR3-altered urothelial carcinoma, narrowing the indication and reshaping CDx and labeling obligations.

Vaibhavi M.Nov 7, 2026Read more
Janssen Wins Full FDA Approval for Erdafitinib